GEM 21S Equimatrix Heli Products Mucograft References Download Center Video Education Center Lecture Materials
Professionals Patients Contact Us About Us
PRODUCTS
GEM 21S®
Optimatrix®
Equimatrix®
Heli Products
NEWS
EVENTS
RESOURCES
CONTACT US
PLACE AN ORDER
REQUEST PRODUCT INFORMATION
LOGIN SITE MAP

Products

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SEARCH:
Osteohealth Company   |   Contact Us   |   © 2014 Luitpold Pharmaceuticals, Inc. Company   |   Privacy Policy   |   Terms of Use
DAIICHI SANKYO NAMES NEW PRESIDENT OF US SUBSIDIARY LUITPOLD PHARMACEUTICALS, INC.

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.